News & Press
May 25, 2023
Global Business Reports Interview: CEO Michael Quirmbach Talks on 2023 Capex Investments in Oligonucleotides, Peptides & LNP Formulation
CordenPharma President & CEO Dr. Michael Quirmbach
What are the reasons behind CordenPharma’s record 2022 year?
One of the reasons is the expansion of our business in the key areas of peptides, lipids, injectables, and highly potent and oncology. In 2022 we successfully supported the launch of several new medicines. Furthermore, CordenPharma has continued to make significant CapEx investments in technology and capabilities in the fields of peptides, lipids, and highly potent and small molecules, with most of them to be completed in 2023. For example, we launched strategic investments at our Caponago site with the construction of a GMP LNP manufacturing suite and the installation of a third commercial aseptic fill and finish line. This led to additional capabilities in terms of injectables and LNP manufacturing and uniquely positions us to offer end-to-end capabilities from initial lipid supply to LNP formulation development and final fill and finish.
Can you speak of the strategy behind CordenPharma’s decision to expand its peptide and oligonucleotide manufacturing capacity?
CordenPharma aims to continue expanding in the US and is constantly looking for acquisition opportunities for manufacturing sites, particularly in key biotech hubs such as Boston, MA. We are also considering greenfield opportunities. CordenPharma made a US$60 million investment into our CordenPharma Colorado facility in Boulder, CO, to support a multi-year agreement for the contract manufacturing of a large-volume commercial peptide, as well as to further strengthen both our large and medium-scale peptide manufacturing capacity.
We also recently decided to move back into the oligonucleotide manufacturing space in CordenPharma Colorado, as it has similarities to peptide manufacturing with significant market demand from customers asking for capacity. CordenPharma is uniquely positioned to offer end-to-end solutions for peptides and oligonucleotides from sophisticated formulation development using lipids excipients especially suited for Lipid NanoParticle (LNP) molecules encapsulating mRNA and other xRNA-based vaccines, to fill and finish sterile injectable drug products.
“Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress.”
Are there any technology platforms currently attracting more demand than others?
In terms of peptides, because there are currently more molecules reaching the market, larger quantities are required than a few years ago. As there are only a few companies who can handle this large-scale peptide manufacturing, CordenPharma is perfectly positioned to answer this demand with our world-class site in Colorado, which has space to expand and the capability to handle the extremely large volume of solvents required for the purification of multi 100 kgs of the peptide.
Can you touch upon the Science Based Targets initiative (SBTi), and your focus on driving down global emissions across the company?
The SBTi partnership independently assesses and approves companies’ targets in line with strict criteria, helping to support best practices for ambitious climate action in the private sector. The initiative is a collaboration between the Committee for Development Policy, the UN, and the WWF. Sustainability is our responsibility as a CDMO and has always been important to CordenPharma. Astorg’s emphasis on ESG has amplified the company’s strong focus in this regard. Our mission to reduce our carbon footprint will contribute towards real sustainability as a company, something that is becoming increasingly important for both investors and customers today. We are currently working on our roadmap and have already set some ambitious targets which we will announce next year. We are gathering the data now, as we want our targets to be science-driven and realistic, so it has real value in the long run.
What are CordenPharma’s main goals and ambitions for 2023 and beyond?
These are very exciting times for CordenPharma. Our biggest site in the US is in Boulder, CO, which is an extremely competitive environment. We attract and retain talent by offering a good salary, but also an environment where people have a purpose and can grow within the company. CordenPharma has a good reputation, offers career progression opportunities, and has a collaborative company culture. My outlook for the industry is very positive. I think pharma companies will continue to outsource, so the need for contract manufacturing will grow as more biotechs emerge. Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress.
Essential cookies are required for basic website functions. This ensures that the website functions properly
The technical storage or access that is used exclusively for statistical purposes.
Name | _ga |
---|---|
Provider | google-analytics.com |
Purpose | This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports. |
Cookie life cycle | 2 years |
Name | _gid |
---|---|
Provider | google-analytics.com |
Purpose | This cookie is set by Google Analytics. It stores and update a unique value for each page visited and is used to count and track pageviews. |
Cookie life cycle | 1 Day |
Name | collect |
---|---|
Provider | google-analytics.com |
Purpose | "Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels. |
Cookie life cycle | session |
Name | vuid |
---|---|
Provider | vimeo.com |
Purpose | Collects data on the user's visits to the website, such as which pages have been read. These cookies are used by the Vimeo video player on websites. |
Cookie life cycle | 2 years |
Name | BE_CLA3 |
---|---|
Provider | BrightEdge |
Purpose | Enables data aggregation, analysis and report creation to assess marketing effectiveness and for website performance. |
Cookie life cycle | 37199 days |
Name | YSC |
---|---|
Provider | Youtube |
Purpose | This cookie is set by YouTube to track views of embedded videos. |
Cookie life cycle | session |
Name | __utmc |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. It is not used in most sites but is set to enable interoperability with the older version of Google Analytics code known as Urchin. In this older versions this was used in combination with the __utmb cookie to identify new sessions/visits for returning visitors. When used by Google Analytics this is always a Session cookie which is destroyed when the user closes their browser. Where it is seen as a Persistent cookie it is therefore likely to be a different technology setting the cookie. |
Cookie life cycle | Session |
Name | __utma |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie lasts for 2 years by default and distinguishes between users and sessions. It it used to calculate new and returning visitor statistics. The cookie is updated every time data is sent to Google Analytics. The lifespan of the cookie can be customised by website owners. |
Cookie life cycle | 2 years |
Name | __utmz |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour measure of site performance. This cookie identifies the source of traffic to the site - so Google Analytics can tell site owners where visitors came from when arriving on the site. The cookie has a life span of 6 months and is updated every time data is sent to Google Analytics. |
Cookie life cycle | 6 months 2 days |
Name | __utmb |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour measure of site performance. This cookie identifies the source of traffic to the site - so Google Analytics can tell site owners where visitors came from when arriving on the site. The cookie has a life span of 6 months and is updated every time data is sent to Google Analytics. |
Cookie life cycle | 6 months 2 days |
Name | __utmt |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie determines new sessions and visits and expires after 30 minutes. The cookie is updated every time data is sent to Google Analytics. Any activity by a user within the 30 minute life span will count as a single visit, even if the user leaves and then returns to the site. A return after 30 minutes will count as a new visit, but a returning visitor. |
Cookie life cycle | 30 minutes |
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Name | visitor_id# |
---|---|
Provider | pardot.com |
Purpose | "Used in context with Account-Based-Marketing (ABM). The cookie registers data such as IP-addresses, time spent on the website and page requests for the visit. This is used for retargeting of multiple users rooting from the same IP addresses. ABM usually facilitates B2B marketing purposes." |
Cookie life cycle | 10 years |
Name | visitor_id#-hash |
---|---|
Provider | pardot.com |
Purpose | Used to encrypt and contain visitor data. This is necessary for the security of the user data. |
Cookie life cycle | 10 years |
Name | Google Maps API |
---|---|
Provider | Google Maps |
Purpose | to read user IP address. |
Cookie life cycle | expires immediately |
Name | GPS |
---|---|
Provider | Youtube |
Purpose | YouTube is a Google owned platform for hosting and sharing videos. YouTube collects user data through videos embedded in websites, which is aggregated with profile data from other Google services in order to display targeted advertising to web visitors across a broad range of their own and other websites. |
Cookie life cycle | session |
Name | PREF |
---|---|
Provider | Youtube |
Purpose | This cookie, which may be set by Google or Doubleclick, may be used by advertising partners to build a profile of interests to show relevant ads on other sites. It works by uniquely identifying your browser and device. |
Cookie life cycle | 8 months |
Name | VISITOR_INFO1_LIVE |
---|---|
Provider | Youtube |
Purpose | This cookie is set by Youtube to keep track of user preferences for Youtube videos embedded in sites;it can also determine whether the website visitor is using the new or old version of the Youtube interface. |
Cookie life cycle | 6 months |